Antiarrhythmic drugs: electrophysiological basis of their clinical usage.
Cardiac arrhythmias arise from abnormalities of impulse initiation or impulse conduction or both. A review of the electrophysiological mechanisms of the genesis of cardiac arrhythmias and of the electrophysiological principles of the treatment of the cardiac arrhythmias leads to: categorization of antiarrhythmic drugs into five classes based on their dominant cardiac electrophysiological actions; a series of categories of their effects on impulse initiation and impulse conduction in different types of cardiac cells; and a systematic approach to pharmacological management of cardiac arrhythmias.
Weng
J T
JT
Smith
D E
DE
Moulder
P V
PV
D000200:Action Potentials / Q000187:drug effects; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy / Q000503:physiopathology*; D001283:Atrioventricular Node / Q000187:drug effects / Q000503:physiopathology; D001949:Bretylium Compounds / Q000494:pharmacology / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use; D004071:Digitalis Glycosides / Q000494:pharmacology / Q000627:therapeutic use; D004594:Electrophysiology; D006801:Humans; D007473:Ion Channels / Q000187:drug effects; D010277:Parasympathomimetics / Q000494:pharmacology / Q000627:therapeutic use; D011690:Purkinje Fibers / Q000187:drug effects / Q000503:physiopathology
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D001949:Bretylium Compounds; D002121:Calcium Channel Blockers; D004071:Digitalis Glycosides; D007473:Ion Channels; D010277:Parasympathomimetics; C045166:bretylium